FIELD: medicine.
SUBSTANCE: group of inventions relates to methods of protecting a human subject from neuronal necrosis after exposure of a human subject to an organophosphate nerve agent, protecting a human subject from a decrease in central nervous system function resulting from exposure to an organophosphate nerve agent, to methods of preventing status epilepticus and preventing changes in behavior resulting from exposure to an organophosphate nerve substance, to a method of protecting a human subject from central nervous system dysfunction arising from exposure to an organophosphate nerve agent. Method of protecting a human subject from neuronal necrosis after exposing the human subject to an organophosphate nerve agent comprises administering to the human subject a pharmaceutical composition, containing from 1 mg/kg to 30 mg/kg of dantrolene or its pharmaceutically acceptable salt and 125 mg/kg of azoxime chloride, 2 mg/kg of atropine methylnitrate and 2 mg/kg of midazolam, where the pharmaceutical composition contains dantrolene or a pharmaceutically acceptable salt thereof, mannitol, polysorbate, povidone, an optional pH regulator and water, wherein the pharmaceutical composition is administered to human subject 24 hours or less after the subject is exposed to a nerve agent. Method of protecting a human subject exposed to an organophosphate nerve agent, comprises administering to a human subject a pharmaceutical composition containing from 1 mg/kg to 30 mg/kg of dantrolene or a pharmaceutically acceptable salt thereof and 125 mg/kg of azoxime chloride, 2 mg/kg of atropine methylnitrate and 2 mg/kg of midazolam, where the pharmaceutical composition contains dantrolene or a pharmaceutically acceptable salt thereof, mannitol, polysorbate, povidone, an optional pH regulator and water, wherein the pharmaceutical composition is administered to human subject 24 hours or less after the subject is exposed to a nerve agent. Method of protecting a human subject from a decrease in the function of the central nervous system arising from exposure to an organophosphate nerve substance, comprises administering to a human subject a pharmaceutical composition containing from 1 mg/kg to 30 mg/kg of dantrolene or a pharmaceutically acceptable salt thereof and 125 mg/kg of azoxime chloride, 2 mg/kg of atropine methylnitrate and 2 mg/kg of midazolam, where the pharmaceutical composition contains dantrolene or a pharmaceutically acceptable salt thereof, mannitol, polysorbate, povidone, an optional pH regulator and water, wherein the pharmaceutical composition is administered to human subject 24 hours or less after the subject is exposed to a nerve agent. Method of preventing status epilepticus involves administering to a human subject a pharmaceutical composition, containing from 1 mg/kg to 30 mg/kg of dantrolene or its pharmaceutically acceptable salt and 125 mg/kg of azoxime chloride, 2 mg/kg of atropine methylnitrate and 2 mg/kg of midazolam, where the pharmaceutical composition contains dantrolene or a pharmaceutically acceptable salt thereof, mannitol, polysorbate, povidone, an optional pH regulator and water, wherein the pharmaceutical composition is administered to human subject 24 hours or less after the subject is exposed to a nerve agent. Method of protecting a human subject from central nervous system dysfunction arising from exposure to an organophosphate nerve substance, comprises administering to a human subject a pharmaceutical composition containing from 1 mg/kg to 30 mg/kg of dantrolene or a pharmaceutically acceptable salt thereof and 125 mg/kg of azoxime chloride, 2 mg/kg of atropine methylnitrate and 2 mg/kg of midazolam, where the pharmaceutical composition contains dantrolene or a pharmaceutically acceptable salt thereof, mannitol, polysorbate, povidone, an optional pH regulator and water, wherein the pharmaceutical composition is administered to human subject 24 hours or less after the subject is exposed to a nerve agent. Method of preventing behavior changes arising from exposure to organophosphate nerve substance, comprises administering to a human subject a pharmaceutical composition containing from 1 mg/kg to 30 mg/kg of dantrolene or a pharmaceutically acceptable salt thereof and 125 mg/kg of azoxime chloride, 2 mg/kg of atropine methylnitrate and 2 mg/kg of midazolam, where the pharmaceutical composition contains dantrolene or a pharmaceutically acceptable salt thereof, mannitol, polysorbate, povidone, an optional pH regulator and water, wherein the pharmaceutical composition is administered to human subject 24 hours or less after the subject is exposed to a nerve agent.
EFFECT: group of inventions described above enables effective prevention and protection against the effect of nerve agents.
17 cl, 5 dwg, 5 tbl, 2 ex
